Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV (DPPIVinHIV)

This study has been completed.
Sponsor:
Collaborator:
The Campbell Foundation
Information provided by (Responsible Party):
Kevin Yarasheski, PhD, Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01093651
First received: March 23, 2010
Last updated: January 22, 2014
Last verified: January 2014

March 23, 2010
January 22, 2014
June 2010
June 2011   (final data collection date for primary outcome measure)
  • CD4+ T-cell Count [ Time Frame: Monthly for 4 months ] [ Designated as safety issue: Yes ]
  • Plasma HIV Viremia (Viral Load) [ Time Frame: Monthly for 6 months ] [ Designated as safety issue: Yes ]
    Percentage of participants with plasma HIV RNA copy number less than 48 copies/mL
  • CD4+ T-cell count [ Time Frame: Monthly for 6 months ] [ Designated as safety issue: Yes ]
  • Plasma HIV RNA copy number [ Time Frame: Monthly for 6 months ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01093651 on ClinicalTrials.gov Archive Site
  • Soluble TNFR2; Serum Biomarkers of Immune Activation [ Time Frame: Baseline, week 8, week 16 ] [ Designated as safety issue: No ]
    serum soluble tumor necrosis factor receptor-2 concentration
  • SDF1α; Serum Biomarkers of Immune Activation [ Time Frame: Baseline, week 8, week 16 ] [ Designated as safety issue: No ]
    serum stromal cell-derived factor-1α concentration
  • RANTES; Serum Biomarkers of Immune Activation [ Time Frame: Baseline, week 8, week 16 ] [ Designated as safety issue: No ]
    serum Regulated on Activation, Normal T cell Expressed and Secreted concentration
  • Oral Glucose Tolerance [ Time Frame: Baseline, week 8, week 16 ] [ Designated as safety issue: No ]
    Area under the 75-gr oral glucose tolerance curve (AUCg) based on plasma glucose values measured at 0, 30, 60, 90, and 120 mins post-glucose challenge.
  • Self-reported Symptoms [ Time Frame: Monthly for 4 months ] [ Designated as safety issue: Yes ]
    Cumulative number of self-reported symptoms based on the Division of AIDS Grading Scale for the Severity of Adult Adverse Events (0-4 scale where 0 is no new symptoms, 4 is serious adverse event or toxicity)
  • Serum biomarkers of immune activation [ Time Frame: Monthly for 6 months ] [ Designated as safety issue: No ]
    Serum SDF-1α, RANTES, soluble TNFR2 levels
  • Adverse events/Toxicity grading [ Time Frame: Monthly for 6 months ] [ Designated as safety issue: Yes ]
    Division of AIDS Grading Scale for the Severity of Adult and Pediatric Adverse Events
Not Provided
Not Provided
 
Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV
A Blinded Randomized Controlled Pilot Immunologic and Virologic Safety Trial of an FDA-approved DPPIV-inhibitor in HIV+ Men and Women

We will test the safety of a new class of anti-diabetes compounds (DPPIV-inhibitors) in people living with HIV. Future trials will examine efficacy for treating diabetes and reducing cardiovascular disease risk in people living with HIV.

Human immunodeficiency virus (HIV)-infection and treatment with antiretroviral therapies are associated with several cardiometabolic risk factors; insulin resistance, diabetes, dyslipidemia, central adiposity, that increase risk for MI and stroke. A new class of drugs used to treat type 2 diabetes has been introduced; Dipeptidyl peptidase-IV (DPPIV)-inhibitors (Januvia®, Onglyza®, alogliptin). Dipeptidyl peptidase-IV (DPPIV)-inhibition could be a safe and effective therapy for HIV-associated insulin resistance and diabetes. However, no safety data exist. The research question is: If HIV+ adults with stable immunologic (CD4+ T-cell count >350 cells/μL) and virologic (plasma HIV RNA <50 copies/mL) function are given a DPPIV-inhibitor would their CD4+ T-cell count and plasma HIV RNA level increase, decrease, or stay the same? Theoretically, DPPIV-inhibition could enhance their immune system by increasing SDF-1α levels; a potent inhibitor of HIV-entry into T-cells, or harm the HIV+ immune system by inactivating CD26 on immune cells. We hypothesize that DPPIV-inhibition will not harm the immune system in HIV+ people. We propose a blinded randomized controlled pilot safety trial of an FDA-approved DPPIV-inhibitor in virologically- and immunologically-stable HIV+ men and women. We will monitor CD4+ T-cell count, plasma HIV RNA levels, immune activation markers, and safety outcomes (lipid/lipoprotein profiles, blood pressure, kidney and liver function) during 4-6 months of DPPIV-inhibitor exposure vs placebo in 20 HIV+ adults. If safety is confirmed, the efficacy of DPPIV-inhibition in HIV+ with insulin resistance will be tested in future trials that examine potential glucoregulatory and cardiovascular benefits.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
  • Diabetes
  • Insulin Resistance
  • Drug: Sitagliptin
    100 mg sitagliptin daily for 4-6 months
  • Drug: Placebo
    Daily placebo for 4-6 months
  • Experimental: DPPIV inhibition
    Four to six months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count >350 cells/µL) and virologic (plasma HIV RNA <50 copies/mL) status.
    Intervention: Drug: Sitagliptin
  • Placebo Comparator: Placebo
    Four to six months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count >350 cells/µL) and virologic (plasma HIV RNA <50 copies/mL) status.
    Intervention: Drug: Placebo
Goodwin SR, Reeds DN, Royal M, Struthers H, Laciny E, Yarasheski KE. Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study. J Clin Endocrinol Metab. 2013 Feb;98(2):743-51. doi: 10.1210/jc.2012-3532. Epub 2012 Dec 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
June 2012
June 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Thirty 18-65 yr old HIV-infected men and women (with source documentation of HIV status) who are stable on any antiretroviral therapy (cART) regimen
  2. Have stable (at least the past 12-months) immunologic (>350 CD4+ T-cells/µL) and virologic (<50 copies HIV RNA/mL) status.
  3. BMI 18-42kg/m2;
  4. Normal blood chemistry for at least 1 month prior to enrollment;
  5. Platelet count > 30,000/mm3, absolute neutrophil count >750/mm3, transaminases < 2.5x the upper limit of normal (ULN).
  6. Long-term non-progressors (not on ART) are not eligible.

Exclusion Criteria:

  1. CD4+ T-cell count <350 cells/µL or detectable plasma HIV RNA (>50 copies HIV RNA/mL) within the past 12-months. During the study, if CD4+ T-cell count declines by >100 cells/µL, or if plasma HIV RNA becomes detectable (>50 copies HIV RNA/mL after repeat analysis 2wks apart), and the participant denies any lapse in their anti-HIV medication regimen, the study medication will be stopped and an adverse event documented. If at any time during the study, two participants experience a reduction in T-cell count >100 cells/µL, or their plasma HIV RNA levels become detectable (>50 copies HIV RNA/mL after repeat analysis 2wks apart), and they are confirmed (by unblinding) to have received sitagliptin, the study will be stopped for serious safety concerns.
  2. Systemic, secondary or opportunistic infection within past 12-months.
  3. Fasting glucose intolerance (FBG >100mg/dL), fasting hyperinsulinemia (>15µU/mL), or fasting insulin resistance (Homeostasis model for insulin resistance (HOMA) >3.0). Any agents that might alter glucose metabolism (insulin, TZDs, metformin, glucocorticoids, sulfonylurea, corticosteroids, megace, rhGH, GH-secretagogue) during the 3 months prior to enrollment or at any time during enrollment. Volunteers with T2DM, IDDM or diabetic ketoacidosis will not be enrolled.
  4. History of serious CV disease or NYHA Functional Class III or IV, (e.g., recent MI, unstable angina, edema, CHF, CAD, CABG, valve disease (murmur), stroke, uncontrolled high blood pressure (resting >160/95 mmHg), irregular heart rhythm, resting ST-segment depression >1mm). Treatment with medications for a CV condition (cardiac glycosides α- or ß-blockers). Some antihypertensive medications (calcium-channel blocker, diuretic, angiotensin II receptor blockers (ARB), angiotensin converting enzyme inhibitors (ACE)) will be permitted.
  5. Moderate to severe renal insufficiency. Serum creatinine >1.7 mg/dL (men) >1.5 mg/dL (women).
  6. Known allergy or hypersensitivity to DPPIV-inhibitors.
  7. Plan to change anti-HIV medication regimen or prophylaxis for opportunistic infection within 6-months of starting study.Transitions among efavirenz-based regimens will be allowed (e.g., Efavirenz + lamivudine + zidovudine (combivir) to Efavirenz + emtricitabine + tenofovir (Atripla)).
  8. Lipid-lowering medications are permitted (fibrate or statin or niacin), but must be stable on that agent for at least 3 months prior to enrollment. Lipid-lowering agents cannot be started during the treatment period.
  9. Chronic hepatitis B infection (HB surface antigen positive). Active hepatitis C infection (detectable Hep C RNA). Those who have cleared hepatitis B or C infection are eligible.
  10. Hematocrit <34% in men or <25% in women with symptoms (fatigue, "tired-legs", shortness of breath). Hemoglobin <10 gm/100ml with symptoms.
  11. Nausea, vomiting, diarrhea (>4 loose stools/day) that are unresponsive to treatment. History of eating disorder or significant GI-disease.
  12. Pregnant or nursing mothers. Women must agree to use an acceptable form of birth control during the study. If birth control pills are used, the woman must be stable on these medications for at least 6 months prior to enrollment.
  13. Active malignancy or treatment with chemotherapeutic agents or radiation therapy (within past 12 months).
  14. >10% unintentional body weight loss during the 12 months prior to enrollment.
  15. "Blinded" investigational drugs/medications during the 3 months prior to enrollment that will not be unblinded before enrollment. Open-label investigational drugs are permitted (within past 3 months, no plan to stop during enrollment and not known to affect glucose, lipid, adipose tissue or liver metabolism).
  16. Over the counter agents that might alter glucose, lipid, or adipose tissue metabolism (e.g., creatine monohydrate, chromium picolinate, amino acid/protein supplements, medium- or long-chain fatty acids) within 1 month of enrollment. These supplements are not permitted during the treatment period.
  17. Reduced cognitive function/unable to provide voluntary informed consent. Prisoners are excluded.
  18. Active substance abuse that the physician-scientist believes may compromise safety, compliance, or interfere with study drug or data interpretation.
  19. Any cytokine or anti-cytokine therapy during 3 months prior to enrollment.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01093651
KEY03222010
Yes
Kevin Yarasheski, PhD, Washington University School of Medicine
Washington University School of Medicine
The Campbell Foundation
Principal Investigator: Kevin E Yarasheski, PhD Washington University School of Medicine
Washington University School of Medicine
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP